CGON
CG Oncology, Inc.
78.30$
+4.9%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.1% | 7.9% | 22,427.5% | 7,208.3% | 115.0% | |
| 99.9% | 92.1% | -22,327.5% | -7,108.3% | -15.0% | |
| 176.9% | 15,198.4% | 22,427.5% | 7,208.3% | 2,887.2% | |
| 44.8% | 3,355.0% | 4,853.4% | 2,959.0% | 1,820.0% | |
| 221.6% | 18,545.5% | 4,853.4% | 2,959.0% | 4,707.1% | |
| -121.7% | -18,453.4% | -27,180.9% | -10,067.3% | -4,722.1% | |
| 4.4% | 0.5% | 3,384.3% | – | – | |
| -124.0% | -18,556.5% | -23,827.0% | -7,729.5% | -3,985.0% | |
| -124.0% | -18,556.5% | -23,827.0% | -7,729.5% | -3,985.0% | |
| -119.5% | -18,548.2% | -23,818.6% | -7,726.7% | -3,949.3% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.